• Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors

FORT MYERS, Fla. / Oct 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR^® ST and RaDaR^® 1.0 assays for detecting molecular residual disease (MRD) in solid tumors. NeoGenomics will also present on the progress of its NextGen (whole genome-based) MRD research program, as well as three additional posters highlighting the company’s work in liquid biopsy and genomic profiling across solid tumor types.

The bridging study, “Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types” (PP.41), evaluated matched samples from 166 patients representing 15 solid tumor types. RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. This study provides analytical confirmation that RaDaR ST maintains the performance of RaDaR 1.0, supporting continuity in MRD assessment as the platform is updated. RaDaR ST is currently covered by Medicare for HR+/HER2- breast cancer (>5 years after diagnosis, recurrence monitoring) and HPV- head and neck carcinoma (adjuvant and recurrence monitoring) and has demonstrated utility across multiple tumor types.

“MRD has become an important part of a patient’s journey for cancer surveillance and monitoring,” said Tony Zook, CEO. “This study shows that RaDaR ST delivers equivalent sensitivity as compared to RaDaR 1.0. We are excited to offer clinicians and patients MRD testing optionality with the expected launch of RaDaR ST in Q1 2026. As we continue to invest in novel MRD technologies for the future, the expanding portfolio of MRD solutions will help address unmet needs for sensitive and accurate residual disease detection and monitoring in patients with cancer.”

In addition to the RaDaR ST bridging study, NeoGenomics will present four other posters at ISLB:

• Performance Characterization of a Novel Whole Genome Sequencing Informed MRD Assay (PP.15), evaluating a whole genome-informed, tumor-specific approach to detect ctDNA at very low levels in solid tumors.
• Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels (PP.74), analyzing genomic features of early-stage lung cancers and investigating the relationship between tumor genomics, ctDNA detectability, and clinical outcomes in these patients.
• Validation of NEO │ PanTracer LBx, a Liquid Biopsy Precision Oncology Pan-Solid Tumor Comprehensive Genomic Profiling Assay (PP.05), presenting analytical and clinical validation findings for therapy selection using liquid biopsy.
• Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay (PP.04), assessing liquid biopsy-based comprehensive genomic profiling to detect actionable variants and support treatment decisions in late-stage cancers.

These presentations contribute to NeoGenomics’ growing body of research in liquid biopsy for MRD detection and genomic profiling. The findings reinforce the company’s strategy to advance next-generation molecular testing platforms and expand the role of ctDNA in clinical research and patient management.

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and filed with the SEC on February 18, 2025, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.